Cancer: The cancer indication segment accounts for a significant portion of the bispecific antibodies market. Bispecific antibodies have shown promising results in targeting and combating cancer cells by simultaneously targeting different antigens. The increasing prevalence of various types of cancer and the growing demand for targeted therapies have driven the growth of bispecific antibodies in the cancer indication segment.
Inflammatory Disorders: Bispecific antibodies have also gained traction in the treatment of inflammatory disorders such as rheumatoid arthritis and inflammatory bowel disease. These antibodies work by targeting multiple pathways involved in the inflammatory response, thereby providing a more comprehensive and effective treatment option for patients. The rising incidence of inflammatory disorders worldwide is expected to further fuel the growth of bispecific antibodies in this indication segment.
Autoimmune Disorders: Bispecific antibodies have shown potential in the treatment of autoimmune disorders by modulating the immune response and targeting specific autoantibodies involved in the pathogenesis of these disorders. The increasing prevalence of autoimmune disorders, coupled with the limited success of existing treatment options, has created a significant market opportunity for bispecific antibodies in this indication segment.